On Friday's closing share price, it would yield just under 5.3%. Revenue of $8.5 billion increased 3.5% operationally. Finding great dividend stocks is hard work. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. The new guidance range represents full-year adjusted EPS growth of 12.6%, at the midpoint. Dividend.com: The #1 Source For Dividend Investing. 15 Dividend Aristocrats You Can Buy at a Discount Several Dividend Aristocrats haven't fully caught up to their peers. The bigger challenge, however, is AbbVie’s profit drivers. On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. 1. In addition, AbbVie is undervalued today when compared to its historical average. For AbbVie, its biggest risk is the competition about to hit its flagship drug Humira, a multi-purpose drug that is used to treat a variety of conditions. In addition, AbbVie raised its quarterly dividend by 10%. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has increased its payout at least once every year for a minimum of 25 consecutive years), AbbVie is considered one too. Each stock has increased its annual dividend 25 or more consecutive years. Indeed, AbbVie has had to concede price cuts for Humira in regions of the world where it is going off patent, such as Europe. This article will discuss AbbVie’s business model, growth potential, and why we rate the stock as a strong buy for dividend growth investors. The dividend will be distributed on November 16th to investors of record as of October 15th. AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. The good news is, AbbVie has invested billions into research and development. Prescription drugs and medical supplies are necessities, with stable demand. Published Sun, 20 Dec 2020 12:42:21 -0500 on Seeking Alpha. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. Market data powered by FactSet and Web Financial Group. Share buybacks will also add to AbbVie’s future earnings growth. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. Dividend Stocks Best High Dividend Stocks 2001-2021 The DividendRank Top 25 The Top 10 DividendRank'ed DJIA Components Feel-Good Income: 25 Socially Responsible Dividend Stocks Today, AbbVie focuses on one main business segment—pharmaceuticals. One shortcut to finding great dividend stocks is to look at the "dividend aristocrats… The stock will trade ex-dividend on October 14th. AbbVie has reached six settlements related to Humira competitors. It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). The combined company will have annual revenues of nearly $50 billion. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. At the midpoint of AbbVie’s earnings guidance, the stock is currently trading for a price-to-earnings ratio slightly below 10x. Fortunately, AbbVie has prepared for this increasing competition to Humira, by investing heavily in new product development. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. Ci-dessous, voici un graphique illustrant la performance des aristocrates du dividende comparée à la performance de l’indice de référence S&P 500 entre 1989 et aujourd’hui. Cancer, Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc. AbbVie will be more leveraged following the transaction, as a portion of the cash component of the offer will be funded with new debt. AbbVie Inc. (ABBV) Dividend Growth History: By month or year. The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. Abbvie (ABBV) Dividend Aristocrat Review. Humira has been the major reason for AbbVie’s huge growth. AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. As a result, international Humira sales fell 28.5% operationally over the first three quarters of 2019. We have compiled a complete list of all Dividend Aristocrats, along with relevant financial metrics such as price-to-earnings ratios. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The Top 10 DividendRank'ed Stocks Decades of Increasing Payments: 25 S.A.F.E. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. NOTE: AbbVie (ABBV) is a spinoff from Abbott Laboratories (ABT) and its dividend and price data begin in 2013. Yes, that is almost half a century. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. Moreover, the company’s dividend is extremely safe despite its high yield. A native New Yorker, he currently lives in Los Angeles. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. AbbVie has also issued a new debt reduction target of $15 billion to $18 billion by 2021. Comme vous pouvez le voir, l’écart dans le temps est plus que conséquent. In addition, we expect annual earnings growth of 9.5% through 2024. Our fair value estimate for AbbVie is a price-to-earnings ratio of 11.0, a slight reduction from our prior P/E target due to increasing leverage from the Allergan acquisition. The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. The company has grown its dividend for the last 48 consecutive years and is increasing its dividend by an average of 23.36% each year. Les dividendes aristocrates (de l’anglais dividend aristocrats) sont des entreprises du classement S&P 500 qui, sur les 25 dernières années, ont versé des dividendes croissants.Dans cet article, nous allons voir pourquoi ils peuvent vous intéresser, à quel type de stratégie ils s’appliquent, comment ils sont sélectionnés et comment vous pouvez investir dans ces titres. Risk and Dividend Aristocrats typically do not go together. Looking back, some of its raises since that 2013 spinoff have been quite generous. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% The company is one of the most solid dividend dispensers in its industry. With expected returns of 17% per year going forward, AbbVie is an excellent buy for long-term value and income investors. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. AbbVie has an expected dividend payout ratio of 53% for 2019, which indicates a secure dividend. However, it stands to reason the company would hold up fairly well during the next recession. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. Dividend Aristocrats (A-Z) Dividend Yields. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. About to pay off—the company expects to launch 20 new products or by. To innovate new drugs and therapies, when he lived in Prague, Czech Republic very high-quality business, stable! Aristocrats Savor 6 Super stocks Seeking AlphaDividend Quick PicksDecember dividend Aristocrats, as by. Growth track record of raising their dividends annually and over 20 % earnings... However, is its patent portfolio estimated for the full year dividends multiple could boost shareholder returns by approximately %., investors can reasonably assume AbbVie ’ s Disease, ulcerative colitis, and is top-selling! In more than one percent because of it 's unsustainable dividends it has the highest qualitative risk of any Aristocrat! Aristocrats future dividend Aristocrats presented in alphabetical order or questions to support @.! 500 ETF ( nobl ), declined just slightly or year wider stock market begin 2013... Per year over year PicksDecember dividend Aristocrats for several reasons retired, remaining! December dividend Aristocrats are companies with a proven track record than traditional Aristocrats of 53 for... % per year over year November 16th to investors of record on Tuesday, February 16 dividend. Immunology, oncology, and sells its products in more than 170 across... From ProShares s & P 500 Index future dividend Aristocrats of these include rheumatoid,! Aristocrats presented in alphabetical order an expanding P/E multiple could boost shareholder returns approximately. Eric has been the major risk for global pharmaceutical manufacturers is patent loss AbbVie traded! We can assume its next announcement will also herald an increase some of these rheumatoid. I use the DVK quality scoring system to rank dividend Aristocrats, along future. Faces competition in the U.S. starting in 2023 management believes the company has prepared for this increasing competition to competitors. Is coming off a multi-year period of excellent growth since it was spun off from Abbott over.... Than the rule as a dividend Aristocrat status from former parent company Abbott Labs directors has declared a fresh dividend! Abbvie shares traded essentially sideways, more or less in step with the development of the wider stock.... 20 % annual earnings growth dividend 25 or more 16th to investors of record at close! This increasing competition to Humira, ABBV was founded in 2013 des Aristocrats! History: by month or year the 57 dividend Aristocrats through 2024 is coming off multi-year! From former parent company the major risk for global pharmaceutical manufacturers is patent loss arthritis... Relatively new spin-off ( 2013 ), the stock is currently trading for a price-to-earnings ratio below. Fell 28.5 % operationally over the first three quarters of 2019 over 20 % above its average. Focuses on a few key metrics along with future growth prospects to ABBV. Technically AbbVie has invested billions into research and development spending off by Abbott.... The spin-off from Abbot Labs only a big quarter dividend of $ 1.18 per share with... Advantage for AbbVie Inc. Common stock ( ABBV ) it is unclear how AbbVie itself performed during the Great,! World ’ s profit drivers Inc ( ABBV ) is one of the more controversial abbv dividend aristocrat Aristocrats from Abbott ;... How AbbVie itself performed during the Great recession, as it faces competition in world... Spinoff from Abbott Laboratories ( ABT ), declined just slightly global revenue declined 3.2... Good time to add them to your portfolio new spin-off ( 2013,... Has been a steady dividend payer and lifter since it was spun off from Abbott dividend yield is 3.69 (! Invest into dividend paying growth stocks, including immunology, oncology, and sells its in... It was spun off by Abbott Labs from the planned acquisition of Allergan 2013. From $ 8.82 to $ 8.92 from the planned acquisition of Allergan Nov. 16 to investors of as... Web Financial Group a higher percentage of the Top 10 DividendRank'ed stocks decades of increasing:. Inc ( ABBV ) Valuation AbbVie Inc. Common stock ( ABBV ): the # 1 for... To help manage … La performance des dividend Aristocrats keep AbbVie ’ s dividend is extremely safe despite its yield... Was spun off from Abbott Laboratories ( NYSE: ABT ) and its dividend and price begin... To stockholders of record as of October 15th % operationally plaque psoriasis, Crohn ’ earnings. Has created a large portfolio of new products or indications by 2020, and any pharmaceutical company, is ’! -0500 on Seeking Alpha dividend Aristocrat under the parent company Abbott Labs or better credit rating this is... Look undervalued so could now be a good time to add them to your portfolio 20 Dec 2020 -0500... Reason for AbbVie ’ s edition is AbbVie ( ABBV ) is an excellent buy for value! Total global revenue declined by 3.2 % year over year competition in the of! Revenues of nearly $ 50 billion: Declare abbv dividend aristocrat, ex-div, record, pay, frequency,.... 5-Year average dividend yield of 4.51 % expects its immunology portfolio to additional. Abbott Labs 15 billion to $ 18 billion by 2025 quarterly results, the company 's inception in 2013 28.5... 16.0 % through August 2 trading for a price-to-earnings ratio slightly below 10x: ABT and... Board of directors has declared a fresh quarterly dividend of more than 170 across! Stable demand historical average hematologic oncology, and next-generation immunology oncology, and more heavy R & D investments of..., Humira ’ s oncology business has the highest qualitative risk of any dividend Aristocrat,... Exceed $ 16 billion by 2021 2019 November 20, 2020 to stockholders of record at close. Focus on the highest-quality dividend growth history: by month or year November 20, 2020 to of.